Hand-foot syndrome with docetaxel: a five-case series

Farhat, Mirna H; El-Saghir, Nagi S.; Shamseddine, Ali

doi:10.5144/0256-4947.2008.374

Cited by 7 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the literature, most reported cases showed that HFS usually occurred 2 weeks into the treatment [4,5,10]. This is in contrast to our patient who developed her symptoms after the 6th weekly dose (80 mg/m 2 ) of paclitaxel.…”

Section: Discussioncontrasting

confidence: 54%

“…For example, docetaxel, which is known to cause HFS in about 6-37% [10], can be switched to paclitaxel with favorable outcome [4]. This was not an option in our patient who was already started on paclitaxel.…”

Section: Discussionmentioning

confidence: 94%

“…There are reported cases where the offending drug was replaced by another similar chemotherapeutic agent, which led to resolution of symptoms [4]. For example, docetaxel, which is known to cause HFS in about 6-37% [10], can be switched to paclitaxel with favorable outcome [4].…”

Section: Discussionmentioning

confidence: 99%

“…Like many other antineoplastic drugs, they have various toxicities that include myelosupression, neuropathies, and mucocutaneous manifestations [2]. Although docetaxel, a widely used taxane chemotherapeutic agent, has been linked to palmoplantar dysesthesia in clinical trials, clinical practice, and many case reports [3,4,5], such an association has not been as frequently established with paclitaxel, except in 3 reported cases and in 1 prospective study [2,3,6,7]. When HFS is diagnosed, physicians usually discontinue the offending agent, and the syndrome starts to resolve slowly, with residual skin pigmentation in some cases [2,8,9,10,11].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Management of Paclitaxel-Induced Hand-Foot Syndrome

et al. 2013

View full text Add to dashboard Cite

Background: Hand-foot syndrome (HFS), also known as acral erythema or palmoplantar dysesthesia, is a manifestation of painful erythema and dysesthesia mostly occurring in the palms and soles. Although many chemotherapeutic agents have been shown to cause HFS, it remains an uncommon adverse cutaneous manifestation of paclitaxel. Case Report: We report a case of paclitaxel-induced grade 3 HFS in a patient with breast cancer. HFS developed after 6 weeks of paclitaxel weekly infusions. The patient was managed by avoidance of sun exposure and extensive use of sunscreen and moisturizers. The skin lesions stabilized and improved gradually. This allowed us to continue the planned necessary course of 12 weeks of paclitaxel under close surveillance. Conclusion: Paclitaxel-induced HFS can be managed with topical creams and avoidance of sun exposure without the need to discontinue chemotherapy. However, close monitoring for any increase or change in symptoms is warranted.

show abstract

Section: Discussioncontrasting

confidence: 54%

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Management of Paclitaxel-Induced Hand-Foot Syndrome

et al. 2013

View full text Add to dashboard Cite

show abstract

“…3 A literature search of OVID, PubMed and IPA revealed that the majority of case reports describe instances of PPE associated with malignancies such as breast or ovarian cancer. [9][10][11][12][13] To date, there have been very few studies or case reports documenting PPE related to soft tissue sarcoma or bone sarcoma treatment. Of these, the majority report liposomal doxorubicin-associated PPE.…”

Section: Introductionmentioning

confidence: 99%

Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature

Harris

Wang

Carulli

2013

J Oncol Pharm Pract

View full text Add to dashboard Cite

Docetaxel-associated palmar-plantar erythrodysesthesia is rarely reported in literature, particularly when used in the treatment of sarcomas. Here, we report a case of docetaxel-related palmar-plantar erythrodysesthesia in a 28-year-old male with recurrent Ewing sarcoma. Although palmar-plantar erythrodysesthesia has been seen in the literature for 30 years, there has still been little progress in understanding and appropriately addressing this adverse effect. This case report and literature review illustrates an infrequently documented adverse skin reaction and discusses the etiology, presentation, and available treatment options for palmar-plantar erythrodysesthesia.

show abstract